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Abstract
Background: The main objective of this meta-analysis was to determine the clinical benefit of concurrent
chemoradiotherapy (CCRT) compared with radiation alone (RT) in the treatment of nasopharyngeal carcinoma
(NPC) patients in endemic geographic areas.
Methods: Using a prospective meta-analysis protocol, two independent investigators reviewed the publications
and extracted the data. Published randomized controlled trials (RCTs) in which patients with NPC in endemic areas
were randomly assigned to receive CCRT or RT alone were included.
Results: Seven trials (totally 1608 patients) were eligible. Risk ratios (RRs) of 0.63 (95% CI, 0.50 to 0.80), 0.76 (95% CI,
0.61 to 0.93) and 0.74 (95% CI, 0.62 to 0.89) were observed for 2, 3 and 5 years OS respectively in favor of the CCRT
group. The RRs were larger than that detected in the previously reported meta-analyses (including both endemic
and non-endemic), indicating that the relative benefit of survival was smaller than what considered before.
Conclusions: This is the first meta-analysis of CCRT vs. RT alone in NPC treatment which included studies only
done in endemic area. The results confirmed that CCRT was more beneficial compared with RT alone. However,
the relative benefit of CCRT in endemic population might be less than that from previous meta-analyses.
Background
Nasopharyngeal carcinoma (NPC) is a common malig-
nant disease of the head and neck with a high preva-
l e n c ei nS o u t h e r nC h i n aa n dS o u t h e a s tA s i a .I ti s
different from other head and neck cancers because of
unique epidemiology, natural behavior and therapeutic
considerations.
NPC is both a radiosensitive and chemosensitive
tumor. Since the publication of the results of a multi-
centre randomized trial conducted in North America
(Intergroup study 0099) [1], concurrent chemoradiother-
apy (CCRT) has been accepted as standard in the treat-
ment of patients with stage III and IV NPC gradually.
However, the major concern remains in extrapolating
the findings of the intergroup study to patient groups in
the Asian context, where NPC is endemic. Several meta-
analyses and a pooled data analysis [2-5] had shown an
improvement of survival in NPC patients who received
chemotherapy and radiotherapy (CR+RT) versus those
received radiotherapy alone (RT). Unfortunately, it still
remains unclear regarding the benefit of CCRT espe-
cially for endemic population in the previously
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any medium, provided the original work is properly cited.published meta-analyses. This fact is all these meta-ana-
lyses included heterogeneous histological mix of
patients, limited number of studies published, or com-
plexity of study design (CCRT with or without adjuvant
or neoadjuvant chemotherapy versus RT alone). In con-
trast, a number of clinical studies [6-18] mainly focus
on the additional value of CCRT from endemic areas
has been published in recent years.
To gain a better understanding of the potential benefit
of CCRT in endemic population, we undertook a meta-
analysis that pooled data from all published Phase III
randomized controlled trials (RCTs) done in endemic
areas focusing on the impact of CCRT comparing with
RT alone on patients with locally advanced NPC. To
o u rk n o w l e d g e ,t h i si st h efirst meta-analysis that
included only those randomized trials done in endemic
areas to date. The pooled analysis of largest cohort
(1608 patients) should provide a clearer understanding
of the impact of CCRT on the natural history of this
disease.
Methods
A prospective meta-analysis protocol including study
aim, study selection criteria, literature search strategy,
quality control of literature and statistical procedures
was developed. The primary aim of present analysis was
designed to evaluate how the CCRT influenced survival
at 2, 3 and 5 years after treatment compared with RT
alone in endemic area patients with locally advanced
NPC. More specifically, the analysis was designed to
examine the difference in patterns of failure (locoregio-
nal recurrence, distant metastasis) in CCRT and RT
alone treatment group. In addition to the main meta-
analysis, we also compared the survival difference
between the CCRT with/without adjuvant chemotherapy
(AC) and RT alone.
Study Criteria
The selection criteria for eligible studies in this meta-
analysis included published randomized controlled
trials done in endemic area recruiting NPC patients of
Asian origin. Patients were randomly assigned to
receive radiotherapy alone or concurrent chemotherapy
combined with radiotherapy. Patients receiving concur-
rent chemotherapy plus some form of adjuvant che-
motherapy in addition to radiotherapy were also
included in this analysis. The 1997 UICC TNM staging
system was used for the staging of the primary tumor.
CT or MRI was used as the main evaluation method
and adequate doses of radiotherapy was given in both
arms equivalent to at least 64Gy, with conventional
fractionation to the primary lesion. Overall survival
(OS) was the primary outcome measure for measuring
the effect of treatment.
Literature Search Strategy
The meta-analysis aimed to include all the relevant pub-
lished trials done in endemic areas. To conduct a search
of the published literatures, multiple search tools by two
independent investigators were used: 1.Computerized
bibliographic databases: Electronic databases (MED-
LINE, CANCERLIT, and EMBASE) were searched with
the medical headlines such as Nasopharyngeal carci-
noma, Concurrent chemoradiotherapy, radiotherapy,
and randomized controlled trials, to identify potentially
eligible trials. 2. Journal manual search and reference
lists: The computer search was supplemented with man-
ual search of reference lists of all available review arti-
cles, primary studies, abstracts from meetings, and
bibliographies of books. 3. Conference proceedings of
ASCO, ESMO/ECCO, ASTRO and ESTRO.
11 clinical trials including 2252 patients were initially
identified. Among them, 4 trials were secondarily con-
sidered ineligible for different reasons (Figure 1)
[ 1 , 6 - 1 8 ] .I nt o t a l ,4t r i a l sw e r ee x c l u d e d .T h et r i a l
reported by Al-Sarraf et al [1] was excluded because this
randomized trial was conducted in North America. The
trials by Chua DT et al [6] and Mizowaki et al [7] were
excluded in this meta-analysis for these trials not being
randomized trials. The trial by Lin et al [8,9] was
excluded for lack of samples size calculation and intro-
duction of randomization method. It was also excluded
by another earlier meta-analysis by Bertrand Baujat [5]
for not meeting the eligibility criterion of unpredictable
treatment assignment.
Figure 1 A flow chart showing the selection of the trials.
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The trials were reviewed using a list of predefined perti-
nent issues that concerned the characteristics of patients
and treatments. To assess the methodological quality of
RCTs, we have examined the statistical design, the ran-
domization process, the quality control process, the
dropout rate and if potential bias was taken into
account. All analyses followed the intention-to-treat
principle. This meta-analysis was performed according
to preferred reporting items for systematic reviews and
meta-analyses - The PRISMA statement [19].
Method of data retrieves
Two independent investigators reviewed the publications
and extracted the data. The following information was
extracted from each article: 1. Basic information from
papers such as, year of publication, journal name, and
author name etc. 2. Characteristics of patients such as:
age, sex, pathological types, stage, and study duration. 3.
Information of study designation such as: sample size
per group, study design, randomization scheme, inclu-
sion criteria, and type of end point used. 4. Information
of treatment such as: treatment modality, dose of RT,
response rate of treatment, numbers of death, locoregio-
nal recurrence, distant metastasis, withdrawals, and so
on. Available information was extracted and recorded to
a data collection form and entered into electronic
database.
Statistical Analysis
The primary end point of this meta-analysis was OS,
defined as the time from random assignment to death.
Secondary end points were the incidence of local and/or
regional recurrence (LRR) and distant metastasis (DM).
Extraction of summary statistics from the Kaplan-Meier
curve was performed according to standard methods for
survival endpoints proposed by Parmar et al [20]. Stan-
dard techniques for meta-analysis were used [21].
Results were expressed as relative risk (RR) with 95%
confidence intervals (CIs). The RR of survival at 2, 3,
and 5 years and RR of LRR or DM at 3 years were com-
pared between the CCRT and RT alone groups. RR less
than 1 indicated improved survival for the combined-
modality treatment compared with radiotherapy alone.
When the span of the 95% CI given did not include 1,
the result was statistically significant. Before estimation
of a RR, a statistical test for homogeneity was per-
formed. A Dersimonian and Laird random effects model
[22] was used in cases in which statistically significant
heterogeneity between studies likely existed. If no signif-
icant heterogeneity was found, a fixed-effects model was
used to calculate pooled RR and 95% CIs. All analyses
were conducted using Review Manager Version 5.0.24
(Revman; the Cochrane Collaboration; Oxford, England).
Results
Study identification and eligibility
After the selection procedure (Figure 1), 7 trials were
considered eligible [10-18]. The majority of patients
were included after 1990. The characteristics of these
studies are listed in Table 1. Kwong’s trial is a factorially
designed study to test the efficacy of CCRT and adju-
vant chemotherapy (AC) independently [10]. Patients
were divided into four treatment groups: Group A, RT
alone; Group B, CCRT; Group C, RT and AC; Group D,
CCRT and AC. As in our analysis, we only took those
randomized studies, which included comparison
between CCRT vs. RT or CCRT +AC vs. RT. We did
not include the patients in group C for the analysis.
Subsequently for OS and overall locoregional and dis-
tance failure, group A was compared with group B and
D. For subgroup analysis with pure CCRT vs. RT,
groups A and B were compared and with adjuvant
groups A and D were compared.
All 7 trials [10-18] were pooled together and 1608
patients were randomly assigned; of whom 773 received
RT and 835 received combined modality treatment. For
3 years OS, the 6 trials [10-15] were included. Out of 6
studies, in three studies [10,11,14] including 573
patients, CCRT were compared with RT alone whereas
in four studies [10,12,13,15] including 774 patients, AC
was added to CCRT.
Overall survival
Data regarding the OS of all the 7 trials [10-18] were
available. The trial by Kwong et al [10] was not included
in 2 years and 5 years OS calculations due to insufficient
data. The trial by Chen et al [16] was not included in 3
years and 5 years OS calculations for too early to get 3
and 5-year data. Our own trial (Zhang et al [14]) was
n o ti n c l u d e di n5y e a r sO Sc a l c u l a t i o n sa l s of o rt o o
early to get 5 years data. When 2-year overall survival
rates were calculated, it showed significant benefit in
favor of the CCRT treatment with RR of 0.63 (95% CI,
0.50 to 0.80). 3-year OS also showed significant benefit
in favor of the CCRT treatment with RR of 0.76 (95%
CI, 0.61 to 0.93). 5 years OS was significantly better in
favor of the CCRT treatment groups with an RR of 0.74
(95% CI, 0.62 to 0.89) (Figure.2).
For the second part of the analysis, we found that
CCRT without AC was better than RT alone for 3 years
OS. CCRT vs. RT showed RR of 0.66 (95% CI, 0.48 to
0.92) for 3 years OS, likewise CCRT+AC vs. RT showed
RR of 0.83 (95% CI, 0.63 to 1.09) (Figure 3).
Locoregional Recurrence
Data regarding the absolute number of locoregional
recurrence rate (LRR) for 3 years were available in the
6 studies [10-15]. A significant overall benefit in favor
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Page 3 of 10of the addition of chemotherapy was found with RR of
0.67 (95% CI, 0.49 to 0.91). The failure rate of locore-
gional control of CCRT group seems better compared
to the RT alone group, the difference was significant
(Figure. 4).
Additionally, the RR for 3 years LRR of CCRT vs. RT
alone [10,11,14] and the LRR of CCRT+ AC vs. RT
alone [10,12,13,15] were also calculated. LRR of CCRT
without AC group had the RR of 0.74 (95% CI, 0.47 to
1 . 1 7 )c o m p a r e dw i t hR Ta l o n e .T h eg r o u pw i t hC C R T
plus AC showed the RR of 0.65 (95% CI, 0.45 to 0.95)
(Figure.4).
Distant Metastasis
Data regarding the absolute number of distant metasta-
sis rate (DMR) in 3 years were provided in 6 trial
reports [10-15]. A significanto v e r a l lb e n e f i ti nf a v o ro f
the addition of chemotherapy was found with RR of
0.71 (95% CI, 0.58 to 0.88) (Figure. 5).
The RR for DMR of CCRT vs. RT alone [10,11,14] and
DMR of CCRT +AC vs. RT alone [10,12,13,15] were also
calculated. The CCRT group had the RR of 0.71 (95% CI,
0.51 to 0.99) compared with RT alone and the group
with CCRT plus AC showed the RR of 0.71 (95% CI, 0.54
to 0.92) compared with RT alone (Figure. 5).
Table 1 Summary of studies included in the meta-analysis
Study No. of
patients
Inclusion
period
Group Histology
(WHO
grade, No.)
Stage Radiotherapy Chemotherapy
I II III Concurrent Adjuvant
Kwong
et al, [10]
2004
165 1995-2001 CCRT
RT
1
1
14
4
95
50
AJCC
stage II
-IV, any
T, any
N
2.5GyFx/5days/wk, primary
site- 68Gy, Nodes- 66Gy, +
10Gy boost dose were
given for pharyngeal
extension and residual
nodes
UFT 200 mg/day/7
days a wk
Alternating Cisplatin 100
mg/m
2 day1 and 5FU 1
gm/m
2/d day 1-3 and VBM
regimen (Vincristine 2 mg,
bleomycin 30 mg, MTX 150
mg/m
2) every 3wks for 6
cycles.
Chan
et al, [11]
2005
350 1994-1997 CCRT
RT
2
1
12
7
160
168
AJCC
stage II
to IV,
any T,
any N,
M0
66Gy in 33Fx per 6.5 wks +
additional boost in case of
parapharyngeal extension,
residual neck nodes, and/or
residual nasopharyngeal
disease (Brachytherapy)
Cisplatin 40 mg/m
2
in day1 weekly
None
Wee
et al, [12]
2005
221 1997-2003 CCRT
RT
- 100%
grade II
and III
AJCC
stage II
to IV,
any T,
any N
70Gy (2Gy/d in 5Fx/wk for
7 wks)
CDDP 25 mg/m
2/d
for 4 days,
alternatively 30/30/
40 mg/m
2/d for 3
days if patient starts
RT on Wednesday
CDDP 20 mg/m
2/d × 4
days, 5FU 1000 mg/m
2/d ×
4 days
Lee et al,
[13,18]
2005,2010
348 1999-2004 CCRT
RT
- 100%
grade II
AJCC
stage III
and IV,
any T,
N2 or
N3, M0
≥66Gy (2Gy/Fx/d, 5Fx/wk)
+ additional boosts to the
parapharyngeal space, the
primary or nodal sites
when indicated not
exceeding 20Gy
Cisplatin 100 mg/
m
2 × 3wks on days
1,22,43
CDDP 80 mg/m
2 and 5FU
1000 mg/m
2/d every 4 wks
on days 71,99 and 127
Zhang
et al, [14]
2005
115 2001-2003 CCRT
RT
- 100%
grade II
and III
AJCC
stage III
and IV,
any T,
N2 or
N3, M0
70-74Gy (2Gy/Fx/d, 5fx/wk)
+ additional boost in case
of parapharyngeal
extension, residual neck
nodes and/or residual
nasopharyngeal disease
6× Oxaliplatin 70
mg/m
2 weekly
None
Lee et al,
[15,17]
2006,2009
93 1999-2004 CCRT
RT
- 100%
grade II
AJCC
stage III
and IV,
T3-4,
N0-1,
M0
≥66Gy (2Gy/Fx/d, 5Fx/wk)
+ Additional boosts to the
parapharyngeal space, the
primary or nodal sites
when indicated not
exceeding 20Gy
Cisplatin 100 mg/
m
2 × 3wks on days
1,22,43
Cisplatin 80 mg/m
2 and
5FU 1000 mg/m
2/d on
days 71,99 and 127
Chen
et al, [16]
2008
316 2002-2005 CCRT
RT
- 100%
grade II
and III
AJCC
stage III
and
IVA-B,
T1-4,
N0-3,
≥68Gy (2Gy/Fx/d, 5Fx/wk)
in 7 weeks + additional
boost in case of
parapharyngeal extension,
residual neck nodes and/or
residual nasopharyngeal
disease
Cisplatin 40 mg/m
2
day1 weekly × 7wks
Cisplatin 80 mg/m
2 day1
and 5FU 800 mg/m
2/d on
days1-5 every 4wks for 3
cycles.
Abbreviation: CDDP, Cisplatin; UICC, International Union Against Cancer; AJCC, American Joint Committee on cancer; FU, Fluorouracil.
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NPC is most common in Southern China and Southeast
Asia, which accounts for the majority of NPC cases
worldwide. The endemic type of NPC is generally differ-
ent from western counterpart in pathological types,
association with Epstein Barr Virus, natural history, and
treatment. A meta-analysis which consists of patients
purely from the endemic areas was long overdue.
This meta-analysis was designed to directly address the
additional effect of chemotherapy concurrently combined
with radiotherapy (CCRT) in endemic NPC population.
These results suggested that the superior survival observed
with CCRT compared with RT alone may be related signif-
icantly with improvement in the risk of distant metastasis.
Our analysis differed a little from the results of pre-
vious meta-analyses. The RR of 3 years OS (RR = 0.76)
A   2  years  Overall  Survival  
Study or Subgroup
Chan (11,25)
Chen (16)
Lee 9901 (13,18)
Lee 9902 (15,17)
Wee (12)
Zhang (14)
Total (95% CI)
Total events
Heterogeneity: Chi² = 8.60, df = 5 (P = 0.13); I² = 42%
Test for overall effect: Z = 3.78 (P = 0.0002)
Events
19
21
31
7
16
1
95
Total
174
158
172
51
111
59
725
Events
35
42
35
5
22
10
149
Total
176
158
176
42
110
56
718
Weight
23.3%
28.1%
23.2%
3.7%
14.8%
6.9%
100.0%
M-H, Fixed, 95% CI
0.55 [0.33, 0.92]
0.50 [0.31, 0.80]
0.91 [0.59, 1.40]
1.15 [0.39, 3.37]
0.72 [0.40, 1.30]
0.09 [0.01, 0.72]
0.63 [0.50, 0.80]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
B 3 years Overall Survival 
Study or Subgroup
Chan (11,25)
Kwong (10)
Lee 9901 (13,18)
Lee 9902 (15,17)
Wee (12)
Zhang (14)
Total (95% CI)
Total events
Heterogeneity: Chi² = 7.77, df = 5 (P = 0.17); I² = 36%
Test for overall effect: Z = 2.59 (P = 0.010)
Events
35
15
38
9
20
6
123
Total
174
110
172
51
111
59
677
Events
46
9
39
7
32
19
152
Total
176
55
176
42
110
56
615
Weight
29.4%
7.7%
24.8%
4.9%
20.7%
12.5%
100.0%
M-H, Fixed, 95% CI
0.77 [0.52, 1.13]
0.83 [0.39, 1.78]
1.00 [0.67, 1.48]
1.06 [0.43, 2.60]
0.62 [0.38, 1.01]
0.30 [0.13, 0.70]
0.76 [0.61, 0.93]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
C 5 years Overall Survival 
Study or Subgroup
Chan (11,25)
Wee (12)
Lee 9901 (13,18)
Lee 9902 (15,17)
Total (95% CI)
Total events
Heterogeneity: Chi² = 3.14, df = 3 (P = 0.37); I² = 5%
Test for overall effect: Z = 3.29 (P = 0.001)
Events
52
24
55
11
142
Total
174
111
172
51
508
Events
73
42
63
13
191
Total
176
110
176
42
504
Weight
37.9%
22.1%
32.6%
7.5%
100.0%
M-H, Fixed, 95% CI
0.72 [0.54, 0.96]
0.57 [0.37, 0.87]
0.89 [0.67, 1.20]
0.70 [0.35, 1.39]
0.74 [0.62, 0.89]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
Figure 2 Two, Three and Five years Overall Survival of CCRT vs. RT. Forest plot of the risk ratio (RR) of the 2 years, 3 years and 5 years OS
with radiotherapy (RT) alone versus radiotherapy plus concurrent chemotherapy (CCRT). The estimate of the RR of each individual trial
corresponds to the middle of squares and the horizontal line gives 95% CI. The closed diamond shows the overall RR with its 95%CI. RR less
than 1 indicated improved survival for the CCRT compared with RT alone.
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(RR = 0.16-0.60) [2,3,5], indicating that the benefit was
smaller than anticipated (Table 2). The possible explana-
tion for these differences is high proportion of patients
with WHO type I histology in previous meta-analyses.
In the current meta-analysis, almost all the cases were
histologically proven NPC. More than 99.69% of these
cases belonged to the WHO Grade II and Grade III sub-
types. Only about 0.31% of the NPCs belonged to the
WHO Grade I subtype. Whereas in other similar meta-
analyses done in the past [2,3,5], significantly more per-
centage of patients with WHO Grade I type of tumor
were included. As Grade I type of NPC is similar to
squamous cell carcinoma of head and neck, which is
more resistant to RT than Grade II and III type of NPC,
patients with Grade I NPC subtypes may benefit mostly
from CCRT [3,10]. But in endemic areas, most of the
patients are Grade II and III type tumors, which are
more sensitive to RT. In the current meta-analysis, we
found that the contribution of survival benefit of CCRT
A   3 years Overall Survival 
Study or Subgroup
Chan (11,25)
Kwong (10)
Lee 9901 (13,18)
Lee 9902 (15,17)
Wee (12)
Zhang (14)
Total (95% CI)
Total events
Heterogeneity: Chi² = 7.77, df = 5 (P = 0.17); I² = 36%
Test for overall effect: Z = 2.59 (P = 0.010)
Events
35
15
38
9
20
6
123
Total
174
110
172
51
111
59
677
Events
46
9
39
7
32
19
152
Total
176
55
176
42
110
56
615
Weight
29.4%
7.7%
24.8%
4.9%
20.7%
12.5%
100.0%
M-H, Fixed, 95% CI
0.77 [0.52, 1.13]
0.83 [0.39, 1.78]
1.00 [0.67, 1.48]
1.06 [0.43, 2.60]
0.62 [0.38, 1.01]
0.30 [0.13, 0.70]
0.76 [0.61, 0.93]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
B 3 years Overall Survival (without adjuvant) 
Study or Subgroup
Kwong (10)
Chan (11,25)
Zhang (14)
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.53, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 2.50 (P = 0.01)
Events
8
35
6
49
Total
53
174
59
286
Events
9
46
19
74
Total
55
176
56
287
Weight
11.9%
61.8%
26.3%
100.0%
M-H, Fixed, 95% CI
0.92 [0.38, 2.21]
0.77 [0.52, 1.13]
0.30 [0.13, 0.70]
0.66 [0.48, 0.92]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
C 3 years Overall Survival (with adjuvant) 
Study or Subgroup
Kwong (10)
Wee (12)
Lee 9901 (13,18)
Lee 9902 (15,17)
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.74, df = 3 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.35 (P = 0.18)
Events
6
20
38
9
73
Total
57
111
172
51
391
Events
9
32
39
7
87
Total
55
110
176
42
383
Weight
10.5%
36.7%
44.0%
8.8%
100.0%
M-H, Fixed, 95% CI
0.64 [0.25, 1.69]
0.62 [0.38, 1.01]
1.00 [0.67, 1.48]
1.06 [0.43, 2.60]
0.83 [0.63, 1.09]
CCRT RT Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours CCRT Favours RT
Figure 3 Three years Overall Survival of RT alone vs. CCRT with and/or without AC. Forest plots of the risk ratio (RR) of the 3 years OS
with RT alone vs. pure CCRT and 3 years OS with RT alone vs. CCRT + AC. The estimate of the RR of each individual trial corresponds to the
middle of squares and the horizontal line gives 95% CI. The closed diamond shows the overall RR with its 95%CI. RR less than 1 indicated
improved survival for pure CCRT with or without AC compared with RT alone. Kwong_AB: In Kwong’s trial, for subgroup analysis with pure CCRT
vs. RT, group A and B were compared. Kwong_AD: In Kwong’s trial, for subgroup analysis with adjuvant groups, A and D were compared.
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result also implied that NPCs in endemic areas are sen-
sitive to RT. On the other hand, the RT methods are
more aggressive in endemic areas than in other areas
[1,10]. Therefore the margin of benefit potentially
gained with additional chemotherapy may be reduced
[12]. The finding that the RT alone group showed better
5-year survival rate in our analysis than in that reported
by the intergroup study [1] (62% vs 21%) may also sup-
port this hypothesis. The current meta-analysis result
indicated that CCRT was still the most effective treat-
ment modality for the improvement of overall survival,
but the exact magnitude of treatment effect of CCRT in
endemic areas might be less than that previously
reported by other meta-analyses. Further studies should
be carried on exploring less toxic chemotherapy regimen
for CCRT.
In this analysis, we also tried to find if there is any
additional benefit for the patients receiving CCRT plus
some kind of AC. Sub-group analyses showed that both
A 3 years Locoregional control failure 
Study or Subgroup
Chan (11,25)
Kwong (10)
Wee (12)
Zhang (14)
Lee 9901 (13,18)
Lee 9902 (15,17)
Total (95% CI)
Total events
Heterogeneity: Chi² = 8.73, df = 5 (P = 0.12); I² = 43%
Test for overall effect: Z = 2.58 (P = 0.010)
Events
12
22
9
2
14
9
68
Total
174
110
111
59
172
51
677
Events
14
13
10
10
33
5
85
Total
176
55
110
56
176
42
615
Weight
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Figure 4 Three years Locoregional control failure with RT alone vs. CCRT with and/or without AC Forest plot of the risk ratio (RR) of 3
years locoregional control failure with RT alone versus CCRT with and/or without AC. The estimate of the RR of each individual trial corresponds
to the middle of squares and the horizontal line gives 95% CI. The closed diamond shows the overall RR with its 95%CI. RR less than 1 indicated
improved survival for the CCRT compared with RT alone. Kwong_AB: In Kwong’s trial, for subgroup analysis with pure CCRT vs. RT, groups A and
B were compared. Kwong_AD: In Kwong’s trial, for subgroup analysis with adjuvant groups, A and D were compared.
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Page 7 of 10locoregional recurrences and distant failure were
improved in CCRT+AC arms compared with RT alone.
Pooling the results of these studies, the RR of death
with CCRT+AC was not significant (figure 3, P = 0.18).
This lack of survival difference might be due to
increased mortality related to the toxicities of che-
motherapy, and possibly successful salvage after relapse.
Increase of non-cancer deaths due to treatment-related,
incidental, and unknown causes might have also nar-
rowed the actual magnitude of survival gain
[13,15,17,18]. The role of adjuvant chemotherapy
remains to be addressed by additional studies.
There was an indication from a previous trial by Lin
et al [9] that the benefit of AC was associated with so
called high-risk patients who met at least one of the fol-
lowing criteria: (1) nodal size >6 cm, (2) supraclavicular
node metastases, (3) 1992 AJCC stage T4N2, (4) multi-
ple neck node metastases with 1 node >4 cm. As our
analysis did not include enough individual data, we
could not analyze the effect of CCRT and AC vs. RT
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Figure 5 Three years Distant metastasis rates with RT alone versus CCRT with and/or without AC. Forest plot of the risk ratio (RR) for 3
years distant metastasis with RT alone versus CCRT with and/or without AC. The estimate of the RR of each individual trial corresponds to the
middle of squares and the horizontal line gives 95% CI. The closed diamond shows the overall RR with its 95%CI. RR less than 1 indicated
improved survival for the CCRT compared with RT alone. Kwong_AB: In Kwong’s trial, for subgroup analysis with pure CCRT vs. RT, groups A and
B were compared. Kwong_AD: In Kwong’s trial, for subgroup analysis with adjuvant groups, A and D were compared.
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Page 8 of 10alone for the high-risk patients. We recommend that the
future trials should be focused on the high risk patients.
One of the shortcomings of our meta-analysis is that
all information came from published data instead of
individual patient data, which might result in two
sources of bias - publication bias and selection bias. We
used funnel plot to estimate the publication bias. If the
funnel plot is not symmetrical or not integrated then it
suggests that the result may be biased. So we tested it
by using the linear regression model proposed by Egger
[23,24]. In our studies the funnel plot was symmetrical,
suggesting that publication bias was not significant. To
avoid the selection bias, two independent investigators
reviewed the publications and extracted the data. The
heterogeneity between the individual studies was also
evaluated.
This meta-analysis was performed in geographic areas
where NPC is endemic [10-18]. It still remained unclear
whether the results obtained from trials performed in
these endemic areas could be extrapolated to non-
endemic areas.
Conclusions
In conclusion, our meta-analysis based on published
trials in endemic areas showed that the CCRT was the
most effective treatment modality for the improvement
of overall survival in locally advanced NPC. However,
the relative benefit of CCRT in endemic population
might be very different from previously published meta-
analyses. In the future, treatment of NPC should be
individualized, according to recognized prognostic
factors, while recognizing the results of randomized
trials of induction and concurrent CCRT.
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